Mark Jackson, MD

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.